GSK-J4, an inhibitor of both KDM6A and KDM6B, effectively enhanced H3K27me3 modification at NOTCH2 loci and sensitized CRC cells to oxaliplatin therapy (Figure 6E). This evidence concerns the gene KDM6A and colorectal carcinoma.